Announcement under Regulation 30 (LODR)-Investor Presentation

We are submitting the revised Investor presentation on the performance of the Company for the quarter ended 30.06.2022.

23 days ago



Sentiments detected

Positive 28
  • Overview Vision - Established in 1992, today the Company has a ▪ To be a leading global player in the Healthcare presence across more than 80 countries industry with a focus on innovation, quality, worldwide with strong Pan India presence products, processes and markets.

  • - To provide dynamic, scientific, cost-effective antipyretics, Anti-infective, Acne - We have Six state-of-the-art facilities engaged and quality health care solutions to the global Treatment, Gastroenterology, Eectile in manufacturing API’s and FDF’s community through innovation Dysfunction, Anti Protozoals, Cardiology, and dermatology, The Company is one of the largest producers and exporters of Gliclazide, a medicine to treat type-2 diabetes.

  • 6 30 years of Legacy Expanded its API’s portfolio to 20+

  • The company increased its Invest footprints across geography and with expansion and integrated The company started play, Company is on the growth Implement reaching various geographies path.

  • and expanded capacities as The Company started well.

  • ▪ Global market is expected to grow at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028.

  • The country also has a large pool of scientists and engineers with the potential to steer the industry ahead to greater heights.

  • Domestic market is expected to grow 3x in the next decade.

  • India’s domestic pharmaceutical market is estimated at US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030.

  • 15 Pharma Industry Growth Trend in the overall Low Labour Cost helps to reduce contribution of the pharma industry.

  • cost of production and increase margins.

  • Economy Support is in favour of Pharma quality R&D and efficiency improvement companies.

  • Low cost of better R&D and lead to better and innovative production, skilled labour, better quality and better products supply reliability give it a competitive advantage.

  • Research & Development Positive Impact of Pandemic as it opens more avenues for the pharma companies.

  • Investing in Bal Pharma: 17 A play on integration and diversified product-client mix Bal Pharma well poised to deliver sustainable growth over long term

  • good brand recall introduction like Alfuzosin, remain the consistent growth Dabigatran driver ▪

  • BAL Pharma Ltd (BPL) an integrated player with Diversification across multiple geographies, multiple Therapeutic segments has created a sustainable roadmap for long term value creation.

  • Strong presence of segment spread across PAN India and distributed network in contribute a good portion of domestic market - Further adding products in revenue lifestyle disease management therapeutical areas Formulations Wider Product Portfolio + Diversified Therapeutical areas + Entrenched Geographies + Broader Clientele = Growth Visibility + Risk Minimisation

  • 19 Healthy Order Book & Strong Product Pipeline API (including Intermediates)

  • of Export Revenue - Formulation manufacturing facility has got approvals from various International Regulatory Authorities including EU GMP Malta,, MCAZ Zimbabwe TFDA Tanzania, PPB Kenya, NAFDAC Nigeria, SBDMA Yemen, NDA Uganda, NDA Uganda, FDHACA Ethiopia, PMPB Malawi, FDA Philippines and MOH Sudan etc.

  • 21 Domestic Formulations: Increasing Market presence - PAN India Operations Vibrant Multispecialty ▪ 246+ Field Force; 2800+ Stockists ; 41,300+ Doctor Reach - Nutritional supplements; Anti Allergic, Anti- Fungal, Gastro, Gynecological Glyduz and Diabetes and - Presence in 8 states - 127+ Field Force; 338 + Stockists; 12,000+ Doctor Reach

  • The scheme is aimed towards pushing domestic manufacturing of key starting materials (KSMs), drug intermediates and active pharmaceutical ingredients (APIs) to reduce import dependence on such input materials

  • Objective: ▪ BAL pharma has received approval under the PLI scheme and placed under The objective of the scheme is to enhance India’s manufacturing capabilities by ‘Category C’ of the said scheme increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector.

  • One of the further objectives of the scheme is to create global champions out of India who - Company’s incentives on various incremental products turnover in API and per intermediates annum and Formulations are eligible in for Anti 10% has the potential to grow in size and scale using cutting-edge technology and Diabetic and Cardiovascular diseases are eligible for 5%.

  • Incentives: ▪ Expecting ~ ₹500 Mn of incentives over 6 years through this scheme via The rate of incentive on incremental sales (over a base year) of pharmaceutical increased revenue.

  • This will help the company to diversify its product portfolio, increase the top for FY 2022-23 to FY 2025-26, 4% for 2026-27 and 3% for 2027-28.

  • line, and enhance the profitability & margin profile.

  • Impact: Total incremental sales worth ₹2.94 trillion and incremental exports of ₹1.96 ▪ Backed by consistent free cash flow generation, the committed CAPEX will be trillion are expected during the six years.

Negative 0

    Mentioned Phrases & Organizations

    Important keywords detected (20+)

    api (33)
    pharma (25)
    anti (20)
    products (18)
    bal (16)
    manufacturing (16)
    unit (13)
    domestic (13)
    bal pharma (13)
    fdf (12)
    india (11)
    market (11)
    markets (10)
    across (10)
    intermediates (10)
    formulations (10)
    product (10)
    global (9)
    countries (9)
    drugs (9)

    Organizations identified (10+)

    Bal Pharma (7)
    API (5)
    Bal Pharma Limited (1)
    Prescription Drugs (1)
    II The Company (1)
    Diversified Global Markets (1)
    Teva (1)
    Actavis (1)
    Mylan (1)
    Takeda (1)

    Tables extracted (6)

    UnitDosage FormCapacity
    Unit 1FDF1.2 bn Tablets 240 mn Capsules
    Unit 2API120 tonnes per annum
    Unit 3*FDF6mn LVP, 180mn SVP & 6mn Liquid Orals
    Unit 4FDF1.8bn tablets, 250mn capsules & 10mn tubes
    Unit 5Intermediates70 tonnes per annum
    Unit 6API180 tonnes per annum

    Features are experimental.